Latest Administration News

Platformo Ltd reported a modest 5% revenue increase in 2025 driven by its Malaysian subsidiary Biztrak, but faced a higher net loss due to regulatory delays and increased corporate advisory costs.

Peak Processing Limited reported a sharp 47.7% revenue drop and a 257.7% increase in losses for H1 2026, alongside a significant asset impairment and ongoing going concern concerns.

Recce Pharmaceuticals reported a doubling of its net loss for the half-year ended December 2025 amid significant progress in its anti-infective drug development and a substantial funding boost. The company is advancing Phase 3 trials and expanding its patent portfolio while managing financial pressures.

Epsilon Healthcare Limited has reported a robust recovery in 2025, with revenue climbing 68% to $9.39 million and net losses shrinking by 63%, driven by growth in contract manufacturing and a new pharmacy division.

Janus Electric Holdings reported a 46% increase in net loss to $4.93 million for the half-year ended December 2025, driven by rising costs despite a 33% revenue boost. The company faces funding uncertainties as it pursues key investments and operational scale-up.

1414 Degrees Ltd posted a steep 192% rise in half-year losses to $3.86 million, while advancing its silicon-based energy storage and hydrogen technologies. The company also faces uncertainty after its joint venture partner Vast Renewables entered administration.

Avecho Biotechnology reported a 9.3% revenue increase alongside a 41.5% rise in net loss for 2025, while progressing its Phase III CBD insomnia trial and securing a significant licensing agreement with Sandoz.

AJ Lucas Group Limited has swung to a $38.9 million half-year profit, buoyed by a significant UK settlement and improved Australian drilling operations despite revenue pressures.

FlexiRoam Limited has reported a remarkable turnaround with a net profit of AUD 1.42 million for the half-year ended 31 December 2025, driven by a shift to high-margin recurring revenue and cost discipline. The launch of its AI-powered eSIM agent and key partnerships underpin this transformation.

Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.

Lumos Diagnostics reported a 74% increase in its half-year loss to US$4.88 million, despite strong progress with its FebriDx diagnostic test and a landmark US distribution agreement. The company awaits a critical FDA decision that could unlock significant revenue growth.

GLG Corp Ltd reported an 18.7% drop in revenue to USD 54.1 million for the half year ended December 2025, resulting in a net loss amid challenging macroeconomic conditions and tariff pressures. Despite operational efficiencies improving gross margins, the company refrained from declaring an interim dividend.